Actively Recruiting
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Led by MBQ Pharma · Updated on 2024-12-12
48
Participants Needed
4
Research Sites
103 weeks
Total Duration
On this page
Sponsors
M
MBQ Pharma
Lead Sponsor
C
Congressionally Directed Medical Research Programs
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
CONDITIONS
Official Title
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available
- Participants with known brain metastases may be eligible if specific conditions are met
- Life expectancy of at least 6 months as judged by the investigator after starting MBQ-167
- Able to swallow capsules twice daily with a meal
- Investigator evaluates other criteria to determine eligibility
You will not qualify if you...
- Unable to take oral medication or have malabsorption syndrome or uncontrolled gastrointestinal conditions that affect drug absorption
- Female participants who are pregnant or breastfeeding
- Received any anticancer treatment within 4 weeks or investigational agent within 28 days prior to the first dose, or not recovered from acute toxicity greater than Grade 0 or 1 from previous treatment
- Active malignancies other than advanced breast cancer
- Investigator evaluates other criteria to determine exclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Precision Next Gen Oncology & Research Center
Beverly Hills, California, United States, 90212
Actively Recruiting
2
Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI
Sarasota, Florida, United States, 34232
Actively Recruiting
3
Sarah Cannon Research Institute/SCRI
Nashville, Tennessee, United States, 37203
Actively Recruiting
4
FDI Clinical Research
San Juan, Puerto Rico, 00927
Actively Recruiting
Research Team
S
Scott Houston
CONTACT
J
Jose Rodriguez-Orengo, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here